Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer

NCT ID: NCT05249712

Last Updated: 2023-01-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2025-12-01

Brief Summary

This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Darolutamide combined with Androgen-Deprivation Therapy in High-risk/Very high-risk localized prostate cancer. This trial is A prospective, single-arm, multicenter clinical trial. Treatment cycle is 24 weeks,

Detailed Description

High risk prostate cancer (PCa) had worse outcomes on radical treatment results, short-time oncological results, even cancer-specific survival, than those low or mediate risk PCa. Neoadjuvant treatment before radical prostatectomy had been proven to get some benefits on peri-operation results, especially on reduction of tumor volume and minimization of biochemical recurrence. This study will evaluate the efficacy and safety of androgen deprivation therapy (ADT) with Darolutamide in neoadjuvant therapy for surgically resectable high-risk or very high-risk PCa.

Conditions

Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ADT with Darolutamide

Pathological response rate after radical prostatectomy with dalotamide combined with androgen deprivation therapy (ADT) in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer.

Duration of treatment: 28-day cycle of darotamide treatment and 6 cycles of neoadjuvant therapy. ADT treatment continued during neoadjuvant therapy and was discontinued after surgery.

Adjusted dosing: When the serum testosterone concentration cannot be maintained at <50 ng/dL, the dose and type of ADT can be adjusted. Investigators can adjust the dose of darostatide according to the situation.

Group Type: EXPERIMENTAL

Darolutamide 300 mg

Intervention Type: DRUG

600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.

Androgen deprivation therapy

Intervention Type: OTHER

The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.

Interventions

Darolutamide 300 mg

600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.

Intervention Type: DRUG

Androgen deprivation therapy

The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.

Intervention Type: OTHER

Other Intervention Names

Nubeqa, BAY1841788; ADT

Eligibility Criteria

Inclusion Criteria

1. Patients must be ≥ 18 and ≤75 years of age；

2. All patients must have a histologically or cytologically diagnosis of prostate cancer，without distant metastasis, and suitable for radical prostatectomy；

3. All patients meet at least one of the following criteria：

1. multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor ≥ T3；

2. Gleason score of primary tumor ≥ 8；

3. prostate specific antigen (PSA) ≥20 ng/ml； d) Radiographic assessment of regional lymph node metastases (N1)；

4. Eastern Cooperative Oncology Group (ECOG) physical condition score 0- 1；

5. Patients must have adequate organ function： hematologic function：within 28 days prior to registration as evidenced by: white blood cell (WBC) ≥ 4.0 × 109 / L, platelets≥ 100 × 109 / L, hemoglobin ≥ 9 g / dL and international normalized ratio (INR) < 1.5； renal function：within 28 days prior to registration, as evidenced by serum creatinine ≤2×ULN； hepatic function: within 28 days prior to registration, as evidenced by: total bilirubin (TBIL)≤1.5 x upper limit of normal (ULN),and SGOT (AST) and SGPT (ALT) ≤ 2.5 x ULN；

6. Patients must participate voluntarily and sign an informed consent form (ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol.

7. Patients of childbearing potential must be willing to take high-efficiency contraceptive measures during the study period and within 120 days after the last dose of treatment.

Exclusion Criteria

1. Patients with prostate having neuroendocrine, small cell, or sarcoma-like features are not eligible.

2. Patients with low-risk and medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: multiparameter MRI or PSMA PET / CT shows clinical staging of primary tumor < T3, Gleason score of primary tumor < 8, and prostate specific antigen (PSA)。

3. Patients with clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases are not eligible.（any M1）。

4. Patients who have previously received androgen deprivation therapy (medical or surgical) more than 3 months or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy are not eligible

5. Patients with severe or uncontrolled concurrent infections are not eligible。

6. Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration.

7. Patients must not have uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection.

8. Patients must not have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled.

9. The patient is mentally ill, mentally disabled or incapable of giving informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

First Affiliated Hospital of Zhejiang University

OTHER

Sponsor Role: collaborator

The First Affiliated Hospital of Soochow University

OTHER

Sponsor Role: collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

Sponsor Role: lead

Responsible Party

Hongqian Guo

Chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hongqian Guo, Phd

Role: PRINCIPAL_INVESTIGATOR

Nanjing Drum Tower Hospital, affiliated to medical school of Nanjing University

Locations

Hongqian Guo

Nanning, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

Hongqian Guo, Phd

Role: CONTACT

dr.ghq@nju.edu.cn

+86-13605171690

Shun Zhang, Phd

Role: CONTACT

explorershun@126.com

+86-15050589789

Facility Contacts

Hongqian Guo, PhD

Role: primary

References

Zhang X, Zhou F, Lu T, Zhang S, Wei X, Qiu X, Xu L, Guo H, Zhuang J. Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial. World J Urol. 2025 Jan 3;43(1):58. doi: 10.1007/s00345-024-05412-4.

Reference Type: DERIVED

PMID: 39751962 (View on PubMed)

Other Identifiers

IUNU-PC-112

Identifier Type: -

Identifier Source: org_study_id